Cartiva, Inc., Announces Multiple Presentations at American Orthopaedic Foot and Ankle Society Annual Meeting 2017

ALPHARETTA, Ga.–(BUSINESS WIRE)–Cartiva, Inc. (Company), a developer of innovative products for treating cartilage damage and osteoarthritis, announced today that clinical data on its Cartiva Synthetic Implant (SCI) will be presented at the American Orthopaedic Foot and Ankle Society (AOFAS) Annual Meeting taking place July 12-15 at the Washington State Convention Center in Seattle, Washington. The AOFAS is a medical specialty society comprised of more than 2,200 orthopaedic surgeons from the US and abroad who specialize in the care of patients with injuries, diseases and other conditions of the foot and ankle. The presentations include:

• Friday, July 14^th 10:15 AM to 10:20 AM, podium presentation by Mark A. Glazebrook, MSc, MD, PhD, FRCSC, “Revision of Implant to Great Toe Fusion: Did We “Burn a Bridge” With a Synthetic Implant Hemiarthroplasty?”
• Saturday, July 15^th 8:20 AM to 8:25 AM, podium presentation by Judith F. Baumhauer, MD, MPH, “Correlation of Hallux Rigidus Coughlin Grade with First MTP Motion, Intra-operative Cartilage Loss and Treatment Success for 1st MTP Arthrodesis and Hemi-Arthroplasty.” This abstract was selected by the AOFAS Program Committee as one of three finalists for the prestigious Roger A. Mann Award. The Mann award is given in recognition of the best clinical paper accepted for presentation at the annual meeting. The winner of the award will be announced during the meeting on Friday, July 14^th.
• Saturday, July 15^th 9:10 AM to 9:15 AM, podium presentation by Andrew J. Goldberg, OBE, MD, MBBS, FRCS, FRCS (Tr&Orth), “The Influence of Patient Factors on the Outcome of Synthetic Cartilage Implant Hemiarthroplasty versus First Metatarsophalangeal Joint Arthrodesis in Advanced Hallux Rigidus.”

In addition, the Company will sponsor a symposium on Friday July 14^th from 6:30 AM to 8:00 AM, Level 6, Rooms 611 & 612. Entitled “The Difference is DATA™ – Cartiva Synthetic Cartilage Implant for Hallux Rigidus”, the symposium’s faculty includes Judith F. Baumhauer, MD, MPH, Michael J. Coughlin, MD, Timothy R. Daniels, MD, FRCSC, Mark A. Glazebrook, MSc, MD, PhD, FRCSC, David B. Thordarson, MD and Keith L. Wapner, MD.

The Company invites all conference attendees to visit Cartiva exhibitor Booth #1211 for ongoing demonstrations of its Cartiva SCI technology.

About Cartiva, Inc.

Based in Alpharetta, Ga., Cartiva, Inc. develops and markets innovative solutions for patients with cartilage damage and osteoarthritis. Cartiva’s venture investors include New Enterprise Associates and Windham Venture Partners. Additional information is available on the company’s website at www.cartiva.net.